IL15 and neoplasm: These improved PD effects, compared to native interleukins, may be attributed to the FHAB platform’s tumor targeting by binding to albumin (17) and cis presentation of IL-12 and IL-15 (6), resulting in extended in vivo t1⁄2 and tumor retention for prolonged cytokine presentation to immune cells in the TME with limited toxicity.